News
What you need to know about Moderna’s new COVID vaccine, just approved by the FDA
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID vaccine, but only for specific populations: all adults 65 and over and those between 12 and 64 with at least one underlying risk factor as defined by the Centers for Disease Control and Prevention.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...
Moderna Inc. has agreed to do a placebo-controlled trial of its new Covid vaccine that was recently approved by US regulators ...
The second of this two-part article explores what organizations should consider when trying to optimize a mixed team of ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the ...
The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback